Treatment with insulin detemir provides improved glycaemic control and less weight gain compared to NPH insulin in people with diabetes

被引：0

作者：

Garber, AJ

Kim, H

Draeger, E

机构：

[1] Baylor Coll Med, Dept Med, Endocrinol Sect, Houston, TX 77030 USA

[2] Novo Nordisk AS, Clin Stat, Gladsaxe, Denmark

[3] Novo Nordisk AS, Reg Europe, Med Affairs NNRE, CDC Europe, Zurich, Switzerland

来源：

DIABETOLOGIA | 2004年 / 47卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

150

引用

页码：A58 / A58

页数：1

共 50 条

[21] Less weight gain with insulin deternir once daily compared to NPH insulin particularly for obese subjects with type 2 diabetes
Philis-Tsimikas, Athena
Koenen, Christoph
Pedersen, Claus B.
Thorsteinsson, Birger
[J]. DIABETES, 2007, 56 : A130 - A130
[22] Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine:: clinical practice experience from a German subgroup of the PREDICTIVE study
Meneghini, L. F.
Rosenberg, K. H.
Koenen, C.
Merilainen, M. J.
Luddeke, H. -J.
[J]. DIABETES OBESITY & METABOLISM, 2007, 9 (03): : 418 - 427
[23] Insulin detemir added to oral anti-diabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain
Rosenstock, Julio
Davies, Melanie
Home, Philip D.
Larsen, Jens
Tamer, Soren C.
Schernthaner, Guntram
[J]. DIABETES, 2006, 55 : A132 - A132
[24] Treatment with insulin detemir vs NPH during pregnancy in women with gestational diabetes: comparison of glycaemic control and pregnancy outcome
Anastasiou, E.
Kazakou, P.
Antsaklis, P.
Ntali, G.
Sarantopoulou, V.
Daskalakis, G.
[J]. DIABETOLOGIA, 2017, 60 : S437 - S437
[25] Insulin detemir reduces gain in body weight and fat mass in ZDF rats when compared with both NPH and insulin glargine
Fledelius, C.
Damgaard, J.
Vinterby, A.
Ribel, U.
Petersen, J. S.
Sturis, J.
[J]. DIABETOLOGIA, 2008, 51 : S392 - S393
[26] Indian Patients with Diabetes Experienced Better Glycemic Control, Less Weight Gain and Hypoglycaemia with Insulin. Detemir When Switched from NPH and Insulin Glargine in PREDICTIVE™ Study
Kesavadev, Jothydev
Singh, Parminder
Pitle, Shailesh Umakant
Bhttacharyya, Arpandev
Mayya, Raghavendra
Moharana, Ashok Kumar
Pathak, Ankit
Kalra, Sanjay
[J]. DIABETES, 2009, 58 : A528 - A528
[27] Less glucose variability with insulin detemir compared to NPH insulin in subjects with type 1 diabetes undergoing continuous glucose monitoring
Jones, David R.
Clauson, Per
Ong, Stephanie
Mathieu, Chantal
[J]. DIABETES, 2006, 55 : A118 - A118
[28] Superior glycaemic control, less nocturnal hypoglycaemia and less weight gain with insulin detemir relative to NPH insulin in subjects with T1DM treated for 24 months using a treat-to-target concept
Bartley, P. C.
Bogoev, M.
Larsen, J.
Tamer, S. C.
Philotheou, A.
[J]. DIABETOLOGIA, 2007, 50 : S97 - S97
[29] The advantage of less weight gain increases with baseline obesity when insulin detemir rather than NPH insulin is added to oral agents in type 2 diabetes
Hermansen, K
Tamer, SC
[J]. DIABETES, 2005, 54 : A67 - A67
[30] Insulin detemir results in less weight gain than NPH insulin when added to oral agents in type 2 diabetes, with this advantage increasing with baseline obesity
Hermansen, K
Tamer, SC
[J]. DIABETOLOGIA, 2005, 48 : A4 - A5

← 1 2 3 4 5 →